相关实验视频
Updated: Sep 19, 2025

08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.2K
口服JAK抑制剂用于儿科炎症性皮肤病
1Division of Pediatric Dermatology, Department of Dermatology, University of California, San Francisco School of Medicine, San Francisco, California, USA.
Current opinion in pediatrics
|June 16, 2025
概括
简氏激酶 (JAK) 抑制剂对儿科炎症性皮肤疾病,如亚托皮炎和大发性脱发有效. 虽然他们的作用在不断变化,但对于其他疾病,建议仔细考虑风险和益处.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 儿科 儿科 儿科
背景情况:
- 简氏激酶 (JAK) 抑制剂代表了一种用于炎症性皮肤疾病的新型治疗类.
- 它们在儿科人口中的使用正在扩大,需要对当前证据进行审查.
研究的目的:
- 评估JAK抑制剂在患有炎症性皮肤疾病的儿科患者的疗效和安全性.
- 确定JAK抑制剂在儿科皮肤病治疗领域的当前作用和未来潜力.
主要方法:
- 对儿童皮肤病学中JAK抑制剂使用的当前文献进行系统审查.
- 分析已批准的指示,正在进行的临床试验和报告的安全数据,包括黑子警告.
主要成果:
- 雅克抑制剂已被批准用于儿科亚型皮肤炎和大发性脱发症,证明了有效性和安全性.
- 在儿科白风,牛皮,青少年皮肤肌炎和性炎的研究使用正在进行中.
- 在儿科患者中没有观察到任何重大安全问题,包括与FDA黑子警告相关的安全问题.
结论:
- 雅克抑制剂为挑战儿科炎症性皮肤疾病提供了有价值的治疗选择.
- 随着越来越多的数据变得可用,治疗中的最佳位置仍在发展.
- 对风险和益处的个性化评估对于患者的选择至关重要.
相关概念视频
Antiasthma Drugs: Leukotriene Modifiers
505
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
505
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
490
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
490
Inflammatory Bowel Disease IV: Pharmacological Management
205
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
205
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
278
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
278
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
399
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
399
The JAK-STAT Signaling Pathway
9.3K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.3K

